Cover of AI Investment Edge: Stocks, Markets & Money

AI Investment Edge: Stocks, Markets & Money

AI Investment Edge: Stocks, Markets & Money

By: iPulse AI by Future Edge Group
Listen for free

Season's Savings | 0.99 €/month for 3 months

5.99 €/month thereafter - terms apply. Cancel monthly.
Clear, evidence-led conversations about AI investment research, stock theses, and the assumptions behind market forecasts. From iPulse AI, the Open Agentic Investment Research Platform by Future Edge Group: explore the sources and dated research at https://ipulseai.com. Research, not investment advice.

ipulseai.substack.comRusslansing Ramdowar Economics Personal Finance
Episodes
  • Amazon: Bigger Cloud Profits. A Bigger Cash Test. | EP028

    Amazon: Bigger Cloud Profits. A Bigger Cash Test. | EP028
    23 Oct 2026
    Amazon is producing more operating profit while its latest company-defined trailing free cash flow is negative. Can the expensive cloud buildout turn strong demand into spendable cash? This continuous two-presenter discussion examines operating performance, investment returns, dated price scenarios and the evidence that would change the thesis.Explore the asset research* AI Consensus* AI Opinions* Profile & FundamentalsAmazon’s operating engine and its cash commitmentsAmazon serves shoppers through online stores and Prime, merchants through marketplace services, fulfillment and advertising, and enterprises through Amazon Web Services (AWS), which supplies computing, storage, databases and AI infrastructure. Its reported operating segments are North America, International and AWS. Advertising is a revenue category, not a separately disclosed operating-profit segment.* Earnings and financial trend: Q2 2026 sales were US$200.61bn, versus US$167.70bn a year earlier, and operating income was US$27.46bn, versus US$19.17bn. Net income of US$62.65bn includes substantial non-operating investment gains. The investment question requires operating and cash performance, rather than treating headline net earnings as recurring cash.* Profitability and margins: AWS produced US$16.62bn operating income on US$42.23bn sales: a derived 39.36% operating margin. Consolidated margin was 13.69%. A US$551m unrealized energy-contract gain reduced Technology and infrastructure expenses, primarily benefiting AWS. The reported margin is not a purely recurring cash margin; depreciation, pricing and mix still matter.* Balance sheet and leverage: At June 30, cash of US$78.21bn and marketable securities of US$44.78bn totaled US$122.99bn. Long-term debt was US$128.89bn, compared with US$65.65bn at December 31, with a further US$3.33bn current portion. Lease liabilities had a present value of US$109.77bn, comprising US$15.43bn current and US$94.34bn long-term. Liquidity is substantial, with debt and other commitments attached.* Investment intensity: Cash investment grew faster than operating cash flow. The purchases support technology infrastructure, mostly AWS growth, and fulfillment capacity. The reviewed filing does not supply a maintenance-only split; neither all-AI spending nor assured investment payback is established.Q2 other income (expense), net was US$53.42bn before tax, including approximately US$50.5bn of upward Anthropic preferred-stock valuation adjustments. Total non-operating income, including net interest, was US$53.40bn. These gains are separate from AWS sales and operating profit, and they are not cash collected. Subtracting a pre-tax gain directly from after-tax net income would not produce a valid adjusted profit measure.The company-defined cash bridgeFor the trailing twelve months ended June 30, 2026: US$161.40bn operating cash flow − (US$173.03bn gross property-and-equipment purchases − US$4.02bn proceeds and incentives) = −US$7.60bn free cash flow. Net property-and-equipment purchases were US$169.01bn. A year earlier, operating cash flow was US$121.14bn, net purchases were US$102.95bn and free cash flow was positive US$18.18bn. Company-defined FCF excludes acquisitions and other investing flows and differs from the broader −US$11.62bn research-packet measure; the definitions must not be combined.The sourced historical comparison uses consolidated, completed calendar-year operating cash flow: 2021 US$46.33bn; 2022 US$46.75bn; 2023 US$84.95bn; 2024 US$115.88bn; 2025 US$139.51bn. The June 2026 trailing period is separate from an actual completed FY2026.Current reference, dated model scenarios and dividendsThe reference is US$250.39, an Alpaca IEX trade on October 22, 2026 at 15:59:56 New York EDT (19:59:56 UTC). This is a dated trade, not a certified consolidated closing price or a live October 23 quote. The exact ordinary listing is AMZN.NASDAQ/USD, ISIN US0231351067.The September research’s original non-adjusted labels were NEUTRAL for 1Y and BUY for 5Y, on its original US$253.71 September 18, 2026 basis. They are not a fresh rescore at US$250.39. The base path below is the synthesizer’s evidence-weighted quarterly price path, rather than a different averaged-return series.Scenario basis and return calculationThe original fixed endpoint dates remain September 18, 2027 and September 18, 2031, displayed by their actual calendar quarter in the table. The remaining time from the October reference is shorter than a new rolling one or five years. Return = (endpoint price − US$250.39) / US$250.39 × 100. Returns are cumulative price changes, not annualized returns or achieved performance.Fixed base endpoints: cumulative price returns from US$250.39, gross before tax/fees, no reinvestment or dividend uplift.* Dated IEX reference — October 22, 2026: US$250.39 per share; cumulative price return 0%; dividend cash not applicable.* Original 1Y endpoint — Q3 2027: US$278.98 per share; cumulative price return...
    Show more Show less
    18 min
  • Medtronic: A Smaller Company. A Stronger Investment? | EP027

    Medtronic: A Smaller Company. A Stronger Investment? | EP027
    21 Oct 2026
    Medtronic completed the MiniMed separation on 15 October 2026. Does a more focused company offer a stronger investment case? This conversation examines procedure growth, cash conversion and the evidence behind the dated model view.Research basis and the business after MiniMedResearch as of 21 October 2026. Medtronic plc ordinary shares: MDT.NYSE, USD, ISIN IE00BTN1Y115. Read the asset’s Medtronic Consensus research and twenty-quarter forecast for the underlying dated research. The released September labels are Buy at both 1Y and 5Y, including and excluding dividends, on the original USD 92.13 reference dated 18 September 2026. They are not a new rating computed at this episode’s reference price.The 14 October final exchange results specify 252,813,348 MiniMed shares exchanged for 55,032,401 Medtronic ordinary shares. Medtronic confirmed completion on 15 October. This was a split-off exchange by participating shareholders, not a cash sale or an automatic pro-rata distribution to every holder. Formally, a spin-off distributes subsidiary shares while a split-off exchanges parent shares; the conversational opening uses spins-off broadly for divestment, not as a technical definition of a cash sale. Medtronic no longer retains a MiniMed interest. Share retirement and removal of diabetes earnings must be assessed together with transition costs.The continuing device businesses span cardiovascular, neuroscience and surgical technology. Examples include Micra pacemakers, Evolut valves, Affera mapping and ablation, and Hugo robotic assistance. Clinical approval, payer coverage, installation and actual instrument use are different milestones.Four financial findingsThe financial checks use the FY2026 full-year results, first-quarter FY2027 release and quarterly SEC Form 10-Q for 31 July 2026. These consolidated periods precede the completed separation.* Earnings and sales: Q1 FY2027 revenue was USD 9.756 bn, up 13.7% reported and 13.7% on the company’s organic definition. The extra fiscal week contributed an estimated USD 570 m; the organic measure does not remove it. Subtracting that estimated benefit suggests roughly 7% underlying organic growth. The next normal-length quarters are a more useful test than extrapolating 13.7%.* Profitability: FY2026 GAAP operating profit was USD 6.467 bn with a 17.8% margin, essentially flat year over year. Q1 FY2027 GAAP operating profit was USD 1.764 bn and margin 18.1%; adjusted operating profit was USD 2.316 bn and margin 23.7%. Portfolio simplification and procedural mix offer scope for improvement, not a guaranteed margin jump.* Balance sheet: At 31 July 2026, cash USD 1.691 bn plus investments USD 7.128 bn totaled USD 8.819 bn. Current debt USD 2.536 bn plus long-term debt USD 25.617 bn totaled USD 28.153 bn. Goodwill USD 43.187 bn and other intangible assets USD 10.238 bn are substantial. These are dated pre-separation consolidated balances, not a post-split recast or an assurance of dividend safety.* Investment intensity: FY2026 property-and-equipment additions were USD 1.904 bn, or 5.2359% of USD 36.364 bn sales. The maintenance/growth split is unavailable. Research and acquisitions are additional uses of capital. The quarterly filing also reports approximately USD 700 m paid for the Cornerstone Robotics investment during Q2 FY2027. Judge returns on total investment, not factory capex alone.One cash bridge, with historical contextFY2026 operating cash USD 7.330 bn − property-and-equipment additions USD 1.904 bn = company-defined free cash flow USD 5.426 bn. Dividends used USD 3.639 bn; buybacks USD 1.035 bn and acquisitions net of cash acquired USD 0.406 bn were separate uses. FCF is a flow, not cash held at the balance-sheet date. A trailing calculation through Q1 FY2027 is USD 5.426 bn + USD 1.290 bn − USD 0.584 bn = USD 6.132 bn; it still includes diabetes and calendar effects, so it is not an unqualified post-separation run rate.The five-year chart uses comparable company-defined annual FCF from the FY2023 release and comparative cash-flow schedules and FY2026 comparative cash-flow schedules. All years below include the diabetes business; fiscal years are not calendar years.* Fiscal year: FY2022; Operating cash (USD bn): 7.346; PP&E additions (USD bn): 1.368; FCF = operating cash − PP&E (USD bn): 5.978* Fiscal year: FY2023; Operating cash (USD bn): 6.039; PP&E additions (USD bn): 1.459; FCF = operating cash − PP&E (USD bn): 4.580* Fiscal year: FY2024; Operating cash (USD bn): 6.787; PP&E additions (USD bn): 1.587; FCF = operating cash − PP&E (USD bn): 5.200* Fiscal year: FY2025; Operating cash (USD bn): 7.044; PP&E additions (USD bn): 1.859; FCF = operating cash − PP&E (USD bn): 5.185* Fiscal year: FY2026; Operating cash (USD bn): 7.330; PP&E additions (USD bn): 1.904; FCF = operating cash − PP&E (USD bn): 5.426Reference price, scenarios and dividend cashThe recording reference is USD 94.645: Alpaca IEX last available trade on 20 October 2026 at ...
    Show more Show less
    19 min
  • Northrop Grumman: Record Backlog, Tough Delivery | EP026

    Northrop Grumman: Record Backlog, Tough Delivery | EP026
    20 Oct 2026
    Northrop Grumman: Record Backlog, Tough Delivery | EP026AI Investment Edge: Stocks, Markets & Money · Research checked 20 October 2026.Northrop’s record order book answers one question: customers want its systems. The harder investment question is how much becomes profitable delivery and cash after contract costs, factory investment and working capital.Explore the dated Northrop Grumman research at iPulse AI.Dated model view: The released September research assigned Buy at both its one-year and five-year horizons, with fixed endpoints 18 September 2027 and 18 September 2031. These are the ORIGINAL, non-adjusted rating labels on the 18 September 2026 reference of US$527.39, not a new score after today’s results or at the recording price. Current-reference scenario returns below are a separate calculation. The positive view depends on turning strategic demand into profitable production and cash.Finalization price refresh: a separate, later snapshotUS$538.13 was the latest available Alpaca IEX trade checked at finalization: 20 October 2026, 09:33:11.756 New York, Eastern Daylight Time. This is an intraday IEX print, not a certified consolidated close. With the same fixed 18 September 2027/2031 targets, the recalculated base price returns are +8.1079% / +53.8014%. Adding the same illustrative US$9.88/US$49.40 cash gives +9.9439% / +62.9814% gross, before tax and fees, without reinvestment.The continuous recording was completed before the market opened and explicitly uses the dated 19 October US$510.53 reference. Its rounded +14%/+62% price and +16%/+72% cash-inclusive figures remain correct for that recorded basis. The video card labels both snapshots separately. The later quote does not alter the archived model targets or constitute a fresh model rating.What Northrop sells, and who paysNorthrop Grumman develops, builds and supports stealth aircraft, strategic missiles, sensors, communications, space and missile-defense systems. The U.S. government accounted for 84% of 2025 sales, including prime and subcontract arrangements. Long contracts provide work visibility, while contract terms and delivery determine profit. Revenue recognition, customer cash receipts and reported earnings are different things.B-21 Raider and Sentinel make nuclear modernization central to the story. Mission electronics, communications and space diversify the business. Northrop does not own every missile or interceptor platform for which it supplies components.Four financial tests, checked against today’s Q3 resultsThe latest reported quarter ended 30 September 2026, with results released 20 October. The dated September AI consensus emphasized demand versus cash conversion, production economics, funding capacity and heavy investment. The fresh filing checks those four findings rather than silently turning the old research into a new model run.* Earnings and financial trend: Q3 sales were US$11.122bn, up 7% reported from US$10.423bn. Diluted EPS rose to US$7.89 from US$7.67. Research tax credits helped earnings: the effective tax rate fell to 13.4% from 16.9%, while pretax earnings declined 2%. Demand is converting into revenue, but sales growth alone does not explain per-share profit.* Profitability and margins: Q3 GAAP operating margin was 11.4%, versus 11.9% a year earlier. The separate non-GAAP segment margin was 12.1%, versus 12.3%. Aeronautics improved to 10.5% from 9.7%; Mission’s comparison included a prior-year US$68m favorable contract adjustment. Factory learning and contract mix matter; growth did not produce uniform margin expansion.* Balance sheet and leverage: September 30 cash was US$3.744bn, against US$15.197bn debt at carrying value—US$14.433bn long-term plus US$0.764bn current. This excludes lease and pension obligations. There is funding capacity alongside debt service and working-capital needs; a sovereign customer does not make the balance sheet risk-free. Unbilled receivables were US$7.899bn.* Capex and investment intensity: Nine-month capital expenditure was US$775m. The B-21 capacity agreement anticipates about US$2.5bn of company investment across multiple years, rather than a single-year expense. Cash goes out before the hoped-for manufacturing benefits, and favorable returns depend on delivery. The September debate about sustained factory investment remains a useful test, not a guarantee of an immediate cash release.One cash bridge: Q3 operating cash flow US$1.745bn − US$0.306bn capex + US$0.371bn customer-equipment sale proceeds = US$1.810bn company-defined adjusted free cash flow. Before the equipment-sale addition, the narrow CFO-minus-capex subtraction is US$1.439bn. The sale is included under the company’s non-GAAP definition; the whole US$1.810bn is not recurring operating cash. For context, nine-month operating cash was US$1.369bn and reported adjusted free cash flow US$965m. Quarterly and year-to-date amounts should not be interchanged.Current 2026 outlook: Northrop’s October 20 ...
    Show more Show less
    16 min
adbl_web_anon_alc_button_suppression_t1
No reviews yet